To date, more than 9,000 lawsuits have been filed across the country against the makers and distributors of Xarelto. Currently, more than 7,000 cases are pending in New Orleans, Louisiana in the multi-district litigation (MDL) overseen by U.S. District Court Judge Eldon Fallon. There are approximately 1,000 state court cases pending in Pennsylvania, 1,000 cases in Delaware, and additional cases in California state courts.
Xarelto is a blood thinner manufactured by German drug maker Bayer AG and distributed in the U.S. by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson. Xarelto entered the U.S. market in July 2011, and is currently approved for six indications, including reducing the risk of stroke in patients with non-valvular atrial fibrillation; treating deep vein thrombosis and pulmonary embolism, and reducing the recurrence of these conditions; and preventing blood clots in patients following knee or hip replacement surgery.
Xarelto carries a significant risk of severe, uncontrolled internal bleeding, with bleeding most often occurring in the gastrointestinal tract or brain. Patients who experience internal bleeding caused by Xarelto are often subjected to hospitalization, blood transfusions, surgeries, strokes, debilitating sickness and disabilities, and/or death.
According to the Institute of Safe Medication Practices, data from the U.S. Food and Drug Administration shows that Xarelto accounted for the largest number of reported cases of domestic, serious injury among regularly monitored drugs in 2015. In 2015, there was a total of 10,674 reports involving patients on Xarelto, including 1,121 patient deaths and 4,508 injuries requiring hospitalization. The most frequent reports involved bleeding on the brain and in the intestines.
Lawyers at Beasley Allen represent hundreds of clients who were injured by Xarelto, and the firm continues to investigate new Xarelto claims. Additionally, Beasley Allen lawyers have been entrusted with key roles in the national Xarelto litigation. Andy Birchfield, the Section Head for our firm’s Mass Torts Section, is on the Plaintiff Steering Committee (PSC) for the MDL and is serving as the Co-Lead Plaintiffs’ Counsel. Beasley Allen lawyers Gibson Vance (Co-Chair of the State/Federal Coordination Committee) and David Byrne (Co-Chair of the Sales & Marketing Discovery Subcommittee) are also serving in key PSC committee roles.
U.S. District Judge Eldon Fallon has selected four “bellwether” cases to be tried next year in Louisiana, Mississippi, and Texas. The first trial involves Louisiana man Joseph J. Boudreaux, Jr. who suffered severe gastrointestinal bleeding after using Xarelto less than a month. The trial for Mr. Boudreaux’s case will begin on March 13, 2017 in New Orleans. The second trial, scheduled to start in New Orleans on April 24, 2017, involves Louisiana man Joseph Orr, who sued the manufacturers/distributors of Xarelto after his wife died from a brain hemorrhage after taking Xarelto for about a month.
The two Louisiana trials will be followed by a trial in Natchez, Mississippi, beginning on May 30, 2017. The Mississippi trial involves one of Beasley Allen’s clients, Mississippi woman Dora Mingo, who suffered gastrointestinal bleeding after using Xarelto to treat a blood clot in her leg. Ms. Mingo’s gastrointestinal bleed required her to spend several days in the ICU, undergo several blood transfusions, and undergo a life-saving surgical procedure. The fourth Xarelto “bellwether” trial will involve Texas man William Henry, who died due to gastrointestinal bleeding while taking Xarelto. The fourth trial will take place in the Northern District of Texas, but the date has not been determined.
Judge Fallon will oversee all four “bellwether” trials, and Beasley Allen lawyers will be heavily involved in each of those trials. Our lawyers continue to investigate new Xarelto claims and are filing cases on behalf of individuals injured by Xarelto. If you need more information about the Xarelto litigation, contact David Byrne, one of the lawyers in our firm’s Mass Torts Section, at 800-898-2034 or by email at David.Byrne@beasleyallen.com.
Sources: Louisiana Record and The Institute for Safe Medication Practices – Quarter Watch
Contact us today for a free legal consultation with an experienced attorney.
Fields marked *may be required for submission.
If you would like to subscribe to the Jere Beasley Report digital edition, simply visit our Subscriptions page and provide the necessary information or call us at 800-898-2034.
Attorney Advertising - Prior results do not guarantee a similar outcome.